Laboratorios Rubio continues with its international expansion plan
Laboratorios Rubio S.A has submitted to the FDA all the documentation for the registry of 2 blood sample based diagnostic tests, as first step with its international expansion strategy
Liposcale. Each lipoprotein makes a difference, when evaluating the cardiovascular risk. The IVD Liposcale® test makes possible to better assess residual cardiovascular risk from the complete characterization of the lipid profile of lipoproteins from a serum sample. The procedure based on the 2D diffusion nuclear magnetic resonance (NMR) spectroscopy technique facilitates the direct analysis of lipid metabolism. Additionally, to regular clinical parameters, Liposcale® differentiates the properties of the different lipoproteins and their respective subfractions, and characterizes them according to their composition, size, density, and number of each one of them, to evaluate the condition of patients in a faster and more precise way. Therefore, the IVD test allows a more personalized therapy, thus offering the possibility of monitoring the efficacy of the implanted hypolipemiant treatments.
Recently, the Spanish Society of Arteriosclerosis has recommended the clinical use of Liposcale® in the following groups of patients with pathogenic basis associated either with insulin resistance, with early onset or recurrent ACVD2 without CVRF3, rare or complex lipid disorders, or clinical situations in which classical analytical techniques cannot be used.
OWLiver, a non-invasive test for the detection of any harmful phases of metabolic liver disease (MAFLD1, previously known as NAFLD) based on metabolomic technology. A comprehensive and complete diagnosis is obtained by generating the lipidomic fingerprint of the patient to evaluate his/her liver activity. OWLiver® consists of the semi-quantification by means of high-performance liquid chromatography - mass spectrometry (UHPLC-MS) of a series of lipid markers extracted from the patient's serum. After applying a panel of algorithms, OWLiver® diagnosed patients without metabolic liver disease / MAFLD1 or identifies each of the phases of MAFLD1: steatosis, steatohepatitis, or steatohepatitis with significant-advanced fibrosis (F2-F3).
Recently, the “Consensus on Methods for Detection and Referral of Occult Prevalent Liver Diseases” of the Spanish Association for the Study of the Liver (AEEH) has positioned OWLiver® in the algorithm for screening patients at risk of suffering from MAFLD1 after conventional serological indices, and of complementary form and / or alternative to transition elastography.
MAFLD: metabolic dysfunction-associated fatty liver disease, formerly known as NAFLD.
ACVD: Atherothrombotic cardiovascular disease
CVRF: Cardiovascular risk factor
For more information about Liposcale® and OWLiver® test, contact us at labrubio@labrubio.com